Drug Abuse in Cardiovascular Diseases

  • F. FurlanelloEmail author
  • L. Vitali Serdoz
  • L. De Ambroggi
  • R. Cappato


A large amount of substances and their association can lead to worsening of latent or active cardiovascular diseases and, sometimes, to ex-novo cardiovascular diseases.

Negative cardiovascular effects are mainly due to pharmacokinetics of substances, in particular if drugs are administered in combination, or if intake, distribution, and elimination processes are altered; moreover, negative effects can be due to pharmacodynamics of drugs as in the presence of an interaction between an otherwise non-toxic substance and a morphofunctional altered cardiac substrate.

In the first part of this chapter, we systematically describe cardiovascular effects of illicit drugs, as listed by the World Anti-Doping Agency and including different classes of substances, namely, anabolic androgenic steroids, hormones and related substances, β2-agonists, diuretics, stimulants, narcotics, cannabinoids, glucocorticosteroids, alcohol, and β-blockers. The second part is dedicated to cardiovascular effects that can occur during the use and abuse of most common prescription drugs as antipsychotic, antibiotics, anti-viral, antihistaminic, and antineoplastic drugs.


Growth Hormone Attention Deficit Hyperactivity Disorder Illicit Drug Anabolic Steroid Anabolic Androgenic Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tokish JM, Kocher MS, Hawkins RJ. Ergogenic aids: a review of basic science, performance, side effects, and status in sports. Am J Sports Med. 2004;32:1543–53.PubMedGoogle Scholar
  2. 2.
    Dhar R, Stout W, Link SM, Homoud MK, Weinstock J, Estes III M. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc. 2005;80:1307–15.PubMedGoogle Scholar
  3. 3.
    Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med. 2002;32:285–96.PubMedGoogle Scholar
  4. 4.
    Gauthier J. The heart and doping. Arch Mal Coeur Vaiss. 2006;99:1126–9.PubMedGoogle Scholar
  5. 5.
    Estes III M, Link MS, Cannom D, Naccarelli GV, Prystowsky EN, Maron BJ, et al. Report of the NASPE policy conference on arrhythmias and the athlete. J Cardiovasc Electrophysiol. 2001;12:1208–19.PubMedGoogle Scholar
  6. 6.
    Kloner AR. Illicit drug use in the athlete as a contributor to cardiac events. In: Estes NA, Salem DN, Wang PJ, editors. Sudden cardiac death in the athlete. Armonk, NY: Futura; 1998. p. 441–51.Google Scholar
  7. 7.
    Furlanello F, Bentivegna S, Cappato R, De Ambroggi L. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J. 2003;4:829–37.PubMedGoogle Scholar
  8. 8.
    Furlanello F, Vitali Serdoz L, Cappato R, De Ambroggi L. Illicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehabil. 2007;14:487–94.PubMedGoogle Scholar
  9. 9.
    Deligiannis A, Bjornstand H, Carre F, Heidbuchel H, Kouidi E, Panhuyzen-Goedkoop NM, et al. on behalf of the ESC Study Group of Sports Cardiology. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13:687–94.Google Scholar
  10. 10.
    Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med. 2004;351(9):847–9.Google Scholar
  11. 11.
    Waddingyon I, Malcolm D, et al. Drug use in English professional football. Br J Sports Med. 2005;39(4):18–22.Google Scholar
  12. 12.
    Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69–74.PubMedGoogle Scholar
  13. 13.
    Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002;91:21–6.Google Scholar
  14. 14.
    Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet. 2001;10:189–94.PubMedGoogle Scholar
  15. 15.
    Yesalis CE, Bahrke MS. Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:25–35.PubMedGoogle Scholar
  16. 16.
    Nilsson S, Baigi A, Marklund B, Fridlund B. The prevalence of use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health. 2001;11:195–7.PubMedGoogle Scholar
  17. 17.
    Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005;19:571–95.PubMedGoogle Scholar
  18. 18.
    Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med. 2001;11:254–9.PubMedGoogle Scholar
  19. 19.
    Congeni J, Miller S. Supplements and drugs used to enhance athletic performance. Pediatr Clin North Am. 2002;49:435–61.PubMedGoogle Scholar
  20. 20.
    Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med. 2002;12:245–9.PubMedGoogle Scholar
  21. 21.
    Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1–15.PubMedGoogle Scholar
  22. 22.
    Fineschi V, Baroldi G, Monciotti F, Pagliacci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001;125:253–5.PubMedGoogle Scholar
  23. 23.
    Schollert PV, Bendixen PM. Dilated cardiomyopathy in a user of anabolic steroids. Ugeskr Laeger. 1993;155:1217–8.PubMedGoogle Scholar
  24. 24.
    Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitation of dilated cardiomyopathy. Cardiology. 1997;88:218–20.PubMedGoogle Scholar
  25. 25.
    Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90:473–5.PubMedGoogle Scholar
  26. 26.
    Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004;90:496–501.PubMedGoogle Scholar
  27. 27.
    McCarthy K, Tang A, Dalrymple-Hay M. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg. 2000;70:658–60.PubMedGoogle Scholar
  28. 28.
    Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252–62.PubMedGoogle Scholar
  29. 29.
    Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21:225–7.PubMedGoogle Scholar
  30. 30.
    Thiblin L, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000;45:16–23.PubMedGoogle Scholar
  31. 31.
    Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–54.PubMedGoogle Scholar
  32. 32.
    Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormonebinding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk. 1997;4:363–6.PubMedGoogle Scholar
  33. 33.
    Karila T, Hovatta O, Seppala T. Concomitant abuse of anabolic androgenic steroids and human chorionic gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med. 2004;25:257–63.PubMedGoogle Scholar
  34. 34.
    Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med. 2003;24:337–43.PubMedGoogle Scholar
  35. 35.
    Lenders JW, Demacker PN, Vos JA. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur bodybuilders. J Sports Med. 1988;9:19–23.Google Scholar
  36. 36.
    Laseter JT, Russel JA. Anabolic steroids induced tendon pathology: a review of the literature. Med Sci Sports Exerc. 1991;23:1–3.PubMedGoogle Scholar
  37. 37.
    Sullivan ML, Martinez CM, Gallagher EJ. Atrial Fibrillation and anabolic steroids. J Emerg Med. 1999;17:851–7.PubMedGoogle Scholar
  38. 38.
    Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17:1576–83.PubMedGoogle Scholar
  39. 39.
    Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol. 1999;84:364–6, A9.Google Scholar
  40. 40.
    Jlekmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol. 2000;1:11–31.Google Scholar
  41. 41.
    Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med. 2002;32:125–42.PubMedGoogle Scholar
  42. 42.
    Hainline B. Blood doping, erytropoietin and drug testing in athletes. In: Waller BF, Harvey WP, editors. Cardiovascular evaluation of athletes: toward recognizing athletes at risk for sudden death. Newton, NJ: Laennec; 1993. p. 129–37.Google Scholar
  43. 43.
    Scheen AJ. Pharma-clinics: doping with erythropietin or the misuse of therapeutic advances. Rev Med Liege. 1998;43:499–502.Google Scholar
  44. 44.
    Shulman DI, Root AW, Diamond FB, Bercu BB, Martinez R, Boucek Jr RJ. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. J Clin Endocrinol Metab. 2003;88:4095–9.PubMedGoogle Scholar
  45. 45.
    Pirnary F. Doping in sports. Rev Med Liege. 2001;56:265–8.Google Scholar
  46. 46.
    De Paolo EF, Gatti R, Lancerin F, Cappellin E, Spinella P. Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes. Clin Chim Acta. 2001;305:1–17.Google Scholar
  47. 47.
    Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. Br J Sports Med. 2006;40 Suppl 1:i35–9.PubMedGoogle Scholar
  48. 48.
    Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. 2006;117:577–89.Google Scholar
  49. 49.
    Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse. Pract Res Clin Endocrinol Metab. 2000;14:71–7.Google Scholar
  50. 50.
    Dean H. Does exogenous hormone improve athletic performance? Clin J Sport Med. 2002;12:250–3.PubMedGoogle Scholar
  51. 51.
    Rosen T. Supraphysiological doses of growth hormone: effects on muscles and collagen in healthy active young adults. Horm Res. 2006;66 Suppl 1:98–104.Google Scholar
  52. 52.
    Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785–92.PubMedGoogle Scholar
  53. 53.
    Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24:272–7.PubMedGoogle Scholar
  54. 54.
    Hipp AA, Heitkamp HC, Rocker K, Dickhuth HH. Hypertrophic cardiomyopathy – sports – related aspects of diagnosis, therapy and sports eligibility. Int J Sports Med. 2004;25:20–6.PubMedGoogle Scholar
  55. 55.
    Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc. 2003;78:1521–6.PubMedGoogle Scholar
  56. 56.
    Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in human. Chest. 2005;127:2057–63.PubMedGoogle Scholar
  57. 57.
    Bouchard R, Weber AR, Geiger JD. Informed decision-making on sympathomimetic use in sport and health. Clin J Sport Med. 2002;12:209–24.PubMedGoogle Scholar
  58. 58.
    Gray SD, Fatovich DM, McCoubrie DL, Daly FF. Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. MJA 2007;186:336–9.Google Scholar
  59. 59.
    Krome CN, Tucker AM. Cardiac arrhythmia in a professional football player. Was ephedrine to blame? Phys Sports Med. 2003;31:1–12.Google Scholar
  60. 60.
    Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. NZ Med J. 2005;18:1227–37.Google Scholar
  61. 61.
    Hall AP, Henry JA. Acute toxic effects of “Ecstasy” (MDMA and related compounds): overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678–85.Google Scholar
  62. 62.
    Ricaurte GA, McCann UD. Recognition and management of ­complications of new recreational drug use. Lancet 2005;365:2137–45.Google Scholar
  63. 63.
    Rakovec P, Kozak M, Sebestjen M. Ventricular tachycardia induced by abuse of ephedrine in a Young healthy woman. Wien Klin Wochenschr 2006;118(17–18):558–61.Google Scholar
  64. 64.
    Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic peformance: a meta-analysis. JAMA. 2003;289:1537–45.PubMedGoogle Scholar
  65. 65.
    McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA. 2004;291:216–21.PubMedGoogle Scholar
  66. 66.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements contraining ephedra alkaloids. N Engl J Med. 2000;343:1833–8.PubMedGoogle Scholar
  67. 67.
    Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of ‘herbal ecstacy’. J Emerg Med. 1999;17:289–91.PubMedGoogle Scholar
  68. 68.
    Carson P, Oldroyd K, Phadke K. Myocardial infarction due to amphetamine. Br Med J Clin Res Ed. 1987;294:1525–6.PubMedGoogle Scholar
  69. 69.
    Clark BM, Schonfield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25:756–61.PubMedGoogle Scholar
  70. 70.
    Naik SD, Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother. 2004;38:400–3.PubMedGoogle Scholar
  71. 71.
    Nissen SE. ADHD Drugs and cardiovascular risk. N Engl J Med. 2006;354:1445–8.PubMedGoogle Scholar
  72. 72.
    Vitellio B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatric Clin N Am. 2008;17:459–74.Google Scholar
  73. 73.
    Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation. 1992;85:407–19.PubMedGoogle Scholar
  74. 74.
    Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol. 1995;25:113–32.PubMedGoogle Scholar
  75. 75.
    Karch SB. Cocaine cardiovascular toxicity. South Med J. 2005;98:794–9.PubMedGoogle Scholar
  76. 76.
    Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute administration of cocaine in the rat. Am J Cardiol. 1989;63:1529–30.PubMedGoogle Scholar
  77. 77.
    Taylor D, Paroish D, Thompson K, Cavaliere M. Cocaine induced prolongation of the QT interval. Emerg Med J. 2004;21:252–3.PubMedGoogle Scholar
  78. 78.
    Magnano AR, Talathoti NB, Hallur R, Jurus DT, Dizon J, Holleran S, et al. Effect of acute cocaine administration on the QTc interval of habitual users. Am J Cardiol. 2006;97:1244–6.PubMedGoogle Scholar
  79. 79.
    Fuller TE, Milling TJ, Price B, Spangle K. Therapeutic hypothermia in cocaine-induced cardiac arrest. Ann Emerg Med. 2008;51:135–7.Google Scholar
  80. 80.
    Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med. 1992;10:169–77.PubMedGoogle Scholar
  81. 81.
    Turhan H, Aksoy Y, Ozgun Tekin G, Yetkin E. Cocaine-induced acute myocardial infarction in young individuals with otherwise normal coronary risk profile: Is coronary microvascular dysfunction one of the underlying mechanisms? Int J Cardiol. 2007;114:106–7.PubMedGoogle Scholar
  82. 82.
    Mittleman MA, Mintzer D, Maclure M, Togler GH, Sherwood JB, Muller JE. Triggering of myocardial infaction by cocaine. Circulation. 1999;99:2737–41.PubMedGoogle Scholar
  83. 83.
    Parker RB, Perry GY, Horan LG, Flowers NC. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. J Cardiovasc Pharmacol. 1999;34:864–9.PubMedGoogle Scholar
  84. 84.
    Littmann L, Monroe Mh, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc. 2000;75:845–9.PubMedGoogle Scholar
  85. 85.
    Perera R, Kraebber A, Schwartz MJ. Prolonged QT interval and cocaine use. J Electrocardiol. 1997;30:337–9.PubMedGoogle Scholar
  86. 86.
    Guo J, Gang H, Zhang S. Molecular determinants of cocaine block of human ether-a-go-go-related gene potassium channels. J Pharmacol Exp Ther. 2006;317:865–74.PubMedGoogle Scholar
  87. 87.
    Brickner ME, Willard JE, Eichhorn EJ, Black J, Grayburn PA. Left ventricular hypertrophy associated with chronic cocaine abuse. Circulation. 1991;84:1130–5.PubMedGoogle Scholar
  88. 88.
    Su J, Li J, Li W, Altura B, Altura B. Cocaine induces apoptosis in primari cultured rat aortic vascular smooth muscle cells: possible relationship to aortic dissection, atherosclerosis, and hypertension. Int J Toxicol. 2004;23:233–7.PubMedGoogle Scholar
  89. 89.
    He J, Xiao Y, Zhang L. Cocaine induces apoptosis in human coronary artery endothelial cells. J Cardiovasc Pharmacol. 2000;35:572–80.PubMedGoogle Scholar
  90. 90.
    Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, Pomara C, Baroldi G. Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol. 2005;99:277–82.PubMedGoogle Scholar
  91. 91.
    Fanoe S, Jensen GB, Ege P. Proarrhythmic effect of methadone: an alternative explanation of sudden death in heroine addicts. PACE 2006;29 (Suppl 1):S30.Google Scholar
  92. 92.
    Fanoe S, Hvidt C, Ege P, Boje Jensen G. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051–5.PubMedGoogle Scholar
  93. 93.
    Krants MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501–4.Google Scholar
  94. 94.
    Friedman RA. The changing face of teenage drug abuse. The trend toward prescription drugs. N Engl J Med. 2006;354:1448–50.PubMedGoogle Scholar
  95. 95.
    Lindsay AC, Foale RA, Warren O, Henry JA. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol. 2005;104:230–2.PubMedGoogle Scholar
  96. 96.
    Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J. 2005;22:679–80.PubMedGoogle Scholar
  97. 97.
    Campos DR, Yonamine M, de Moraes Moreau RL. Marijuana as doping in sports. Sports Med. 2003;33:395–9.PubMedGoogle Scholar
  98. 98.
    Lorente FO, Peretti-Watel P, Grelot L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addict Behav. 2005;30:1382–91.PubMedGoogle Scholar
  99. 99.
    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–9.PubMedGoogle Scholar
  100. 100.
    Arash A, Mark AW. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol. 2007;118:141–4.Google Scholar
  101. 101.
    Whyte G, Stephens N, Sharma S, Shave R, Budgett R, McKenna WJ. Spontaneus atrial fibrillation in a freestyle skier. Br J Sports Med. 2004;38:230–2.PubMedGoogle Scholar
  102. 102.
    Pirwitz MJ, Willard JE, Landau C, Lange RA, Glamann DB, Kessler DJ, et al. Influence of cocaine, ethanol, or their combination on epicardial coronary arterial dimensions in humans. Arch Intern Med. 1995;155:1186–91.PubMedGoogle Scholar
  103. 103.
    Randall T. Cocaine, alcohol mix in body to form even longer ­lasting, more lethal drug. JAMA. 1992;267:1043–4.PubMedGoogle Scholar
  104. 104.
    Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819–34.PubMedGoogle Scholar
  105. 105.
    Biberdorf DJ, Steens R, Millar TW, Kryger MH. Benzodiazepines in congestive heart failure: effects of temazepam on arousability and Cheyne-Stokes respiration. Sleep. 1993;16(6):529–38.PubMedGoogle Scholar
  106. 106.
    Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328(19):1398–405.PubMedGoogle Scholar
  107. 107.
    Miller J. Managing antidepression overdoses. Emerg Med Serv. 2004;33(10):113–9.Google Scholar
  108. 108.
    Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 2003;23(1):58–77.PubMedGoogle Scholar
  109. 109.
    Shader RI, Greenblatt DJ. More on potassium, the heart, and antipsychotic agents. J Clin Psychopharmacol. 1999;19(3):201–2.PubMedGoogle Scholar
  110. 110.
    Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–58.PubMedGoogle Scholar
  111. 111.
    Shader RI, Greenblatt DJ. Selective serotonin reuptake inhibitor antidepressants: cardiovascular complications–sorting through findings. J Clin Psychopharmacol. 2001;21(5):467–8.PubMedGoogle Scholar
  112. 112.
    Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl. 1989;16:i–iii, 1–40.Google Scholar
  113. 113.
    Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25(1–2):215–21. Review.Google Scholar
  114. 114.
    Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry. 1986;47(5):225–9.PubMedGoogle Scholar
  115. 115.
    Murray JB. Cardiac disorders and antidepressant medications. J Psychol. 2000;134(2):162–8. Review.Google Scholar
  116. 116.
    Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74(6):613–34.PubMedGoogle Scholar
  117. 117.
    Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf. 1993;9(5):346–64.PubMedGoogle Scholar
  118. 118.
    Rolan P. Pharmacokinetics of new antiherpetic agents. Clin Pharmacokinet. 1995;29(5):333–40.PubMedGoogle Scholar
  119. 119.
    Flexner C. HIV-protease inhibitors. N Eng J Med. 1998;338(18):1281–92.Google Scholar
  120. 120.
    Watts RG. Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol. 1991;36(3):217–8.PubMedGoogle Scholar
  121. 121.
    Frishman WH, Sung HM, Yee HC, Liu LL, Keefe D, Einzig AI, Dutcher J. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer. 1997; 21(6):301–60.Google Scholar
  122. 122.
    Broder H, Gottlieb RA, Lepor NE. Chemotherapy and cardiotoxicity. Rev Cardiovasc Med. 2008;9(2):75–83.Google Scholar
  123. 123.
    Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer. 1988;61(1):36–45.PubMedGoogle Scholar
  124. 124.
    Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol. 2002;17:389–419.PubMedGoogle Scholar
  125. 125.
    DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. 1999;21(2):281–95.PubMedGoogle Scholar
  126. 126.
    Barbey JT, Anderson M, Ciprandi G, Frew AJ, Morad M, Priori SG, Ongini E, Affrime MB. Cardiovascular safety of ­second-generation antihistamines. Am J Rhinol. 1999;13(3):235–43.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • F. Furlanello
    • 1
    Email author
  • L. Vitali Serdoz
    • 1
  • L. De Ambroggi
    • 1
  • R. Cappato
    • 1
  1. 1.Center of Clinical Arrhythmology and Electrophysiology, Istituto Policlinico San Donato, IRCCSUniversity of MilanSan Donato MilaneseItaly

Personalised recommendations